Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Sep;28(9):2223-9.
doi: 10.2337/diacare.28.9.2223.

Higher medical care costs accompany impaired fasting glucose

Gregory A Nichols  1 , Jonathan B Brown
Affiliations

Higher medical care costs accompany impaired fasting glucose

Gregory A Nichols et al. Diabetes Care. 2005 Sep.

Abstract

Objective: The purpose of this study was to estimate medical costs associated with elevated fasting plasma glucose (FPG) and to determine whether costs differed for patients who met the 2003 (> or = 100 mg/dl) versus the 1997 (> or = 110 mg/dl) American Diabetes Association (ADA) cut point for impaired fasting glucose.

Research design and methods: We identified 28,335 patients with two or more FPG test results of at least 100 mg/dl between 1 January 1994 and 31 December 2003. Those with evidence of diabetes before the second test were excluded. We categorized patients into two stages of abnormal glucose (100-109 mg/dl and 110-125 mg/dl) and matched each of these subjects to a patient with a normal FPG test (<100 mg/dl) on age, sex, and year of FPG test. All subjects were followed until an FPG test qualified them for a higher stage, dispensing of an anti-hyperglycemic drug, health plan termination, or 31 December 2003.

Results: Adjusted annual costs were dollar 4,357 among patients with normal FPG, dollar 4,580 among stage 1 patients, and dollar 4,960 among stage 2 patients (P < 0.001, all comparisons). After removing patients with normal FPG tests whose condition progressed to a higher stage or diabetes, costs in the normal FPG stage were dollar 3,799. Patients in both stages 1 and 2 had more cardiovascular comorbidities than patients with normal FPG.

Conclusions: Our results demonstrate that abnormal glucose metabolism is associated with higher medical care costs. Much of the excess cost was attributable to concurrent cardiovascular disease. The 2003 ADA cut point identifies a group of patients with greater costs and comorbidity than normoglycemic patients but with lower costs and less comorbidity than patients with FPG above the 1997 cut point.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Annual Medical Care Costs by Fasting Plasma Glucose Stage
Figure 2.
Figure 2.
Annual Medical Care Costs by Fasting Plasma Glucose Stage, Excluding Subjects with Normal Plasma Glucose Who Later Progressed to IFG or Diabetes
See this image and copyright information in PMC

References

    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med. 2002;346(6):393–403. - PMC - PubMed
    1. Tuomilehto J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. - PubMed
    1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072–2077. - PubMed
    1. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: Incremental medical care costs during the first eight years preceding diagnosis. Diabetes Care. 2000;23:1654–1659. - PubMed
    1. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: Incremental medical care costs during the first eight years after diagnosis. Diabetes Care. 1999;22:1116–1124. - PubMed

Publication types